Literature DB >> 12666126

Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.

Jean-Yves Scoazec, Pierre Krolak-Salmon, Olivier Casez, Gérard Besson, Stéphane Thobois, Nicolas Kopp, Armand Perret-Liaudet, Nathalie Streichenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12666126     DOI： 10.1002/ana.10530

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  5 in total

Review 1.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

2.  Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease.

Authors:  Katsuya Satoh; Susumu Shirabe; Katsumi Eguchi; Atsushi Yamauchi; Yasufumi Kataoka; Masami Niwa; Noriyuki Nishida; Shigeru Katamine
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

3.  THERPA: A small molecule database related to prion protein regulation and prion diseases progression.

Authors:  Sol Moe Lee; Wonseok Lee; Yeong Seon Lee; Jin-Soo Yoo; Soo-Jung Park; Heebal Kim; Su Yeon Kim
Journal:  Prion       Date:  2018-05-04       Impact factor: 3.931

4.  Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.

Authors:  John Collinge; Michele Gorham; Fleur Hudson; Angus Kennedy; Geraldine Keogh; Suvankar Pal; Martin Rossor; Peter Rudge; Durre Siddique; Moira Spyer; Dafydd Thomas; Sarah Walker; Tom Webb; Steve Wroe; Janet Darbyshire
Journal:  Lancet Neurol       Date:  2009-03-09       Impact factor: 44.182

5.  Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey.

Authors:  Arthur Petitdemange; Renaud Felten; Jean Sibilia; Thierry Martin; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-19       Impact factor: 5.346
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.